// App-Quantinova.ai

CT316 : A phase I trial of oral TRC102 (methoxyamine HCl) in combination with temozolomide (TMZ) in patients with relapsed solid tumors

Researchers

Presenter

  • Woondong Jeong

Principal Investigators

  • Khanh Do

  • Alice Chen

  • Howard Streicher

  • Richard Piekarz

  • Barbara Conley

  • Jerry Collins

  • James H. Doroshow

  • Jennifer Zlott

  • Lamin Juwara

  • Yvonne Horneffer

  • Robert Kinders

  • Lihua Wang

  • Priya Balasubramanian

  • Larry Anderson

  • Elad Sharon

Medical Centers

  • Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD

  • Division of Cancer Treatment and Diagnosis, Natl Cancer Inst, Bethesda, MD

  • Center for Cancer Research, National Cancer Institute, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Temozolomide

  • Methoxyamine

  • TRC102

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved